RNA microarray analysis of the microdissected lymphoid aggregates demonstrated that upregulation of CCL2 following treatment with a pancreatic cancer vaccine was associated with significantly poorer survival in patients with PDAC (Lutz et al., 2014), providing further evidence on the role of the CCL2/CCR2 axis in the cancer treatment response. This evidence concerns the gene CCL2 and pancreatic neoplasm.